

SHARON E. JOHNATTY, PhD

M: (61) 43116 7357 E: sharon@sugarapple.net.au W: <https://www.sugarapple.net.au/>
<https://www.linkedin.com/in/sharon-johnatty/>

PROFILE

Experienced scientific writer, editor, reviewer and statistics consultant, with over 30 years of academic biomedical research experience at prestigious institutions in the US and Australia. I have had extensive collaborations and interaction with academic and clinical colleagues at international institutions and a significant publication track record, many in high impact journals. I am passionate about enabling the clear and effective communication of scientific concepts and accurate interpretation of data.

EDUCATION

2002: PhD (Epidemiology and Human Genetics): University of Texas School of Public Health (USA)

1999: MS (Epidemiology & Biostatistics): University of Texas School of Public Health (USA)

1985: MS (Biological Sciences): University of Houston (USA)

1979: BSc (Zoology and Botany): University of the West Indies (Trinidad, W.I.)

CAREER HISTORY

2017 – present Owner & Scientific Director, SugarApple Communications (Australia)

- Established new dedicated provider of scientific communication services to both the commercial and academic sectors
- Provision of quality scientific writing and editing services as well as strategic communications and statistical support

2006 – present Research Officer, QIMR Berghofer (Australia)

- Statistical analysis of genetic makers of cancer risk and prognosis as part of large international multi-centre research consortia.
- Developed and managed ovarian cancer chemotherapy and outcome databases
- Co-authored, reviewed and edited over 50 published research manuscripts on women's cancers and cardiovascular disease
- Managed collaborative projects from data acquisition to publication
- Developed collaborative links with pharmaceutical companies and sponsors.
- Taught MBBS Program courses (seminars and e-learning modules)
- Grant Reviewer/Editor for national NHMRC grant applications as part of institutional pre-submission process

- 2004 – 2006 Assistant Professor, University of Florida College of Medicine (USA)**
- Tenure-track position in epidemiology and biostatistics
 - Developed and taught post-graduate level courses (seminars and e-learning modules) in Clinical Trials (design, conduct and interpretation as applied to the pharmaceutical industry) and Genetic & Molecular Epidemiology
- 2002 – 2003 Epidemiology Consultant, Scientific Evidence Inc. (USA)**
- Developed scientific documentation for drug litigation
 - Researched and distilled clinical evidence and data for legal purposes and court proceedings.
- 1984 – 1999 Research Associate, Baylor College of Medicine & University of Texas (USA)**
- Managed research projects and generated data for publications and grants proposals
 - Presented data at scientific conferences and workshops, published academic papers and book chapters
 - Supervised research staff and students
 - Tutored and mentored post-graduate biostatistics students

PROFESSIONAL MEMBERSHIPS

Delta Omega National Public Health Honor Society
American Association for Cancer Research
American Society of Human Genetics
Council of Science Editors
Australasian Medical Writers Association

PEER-REVIEWER (JOURNALS, BOOKS)

Frontiers in Genetics • Lancet Oncology • International Journal of Cancer • PLOS ONE • Cancer Letters • Scientific Reports • Cancer Epidemiology • Journal of Experimental & Clinical Cancer Research • Twin Research and Human Genetics

Multiple Analyses in Clinical Trials: Fundamentals for Clinical Investigators. Lemuel A. Moyé. Chapters 5-8. Springer-Verlag, New York Inc. 2003

SOFTWARE PROFICIENCY

Microsoft Office Suite (proficient with Word, Excel, PowerPoint and Access)

Endnote

Statistical Software

- STATA SE 13.0
- SAS v. 9.4
- The R project for Statistical Computing
- PLINK
- Web-based *in silico* data mining tools e.g. ENCODE, Haploview, KMPlotter

SELECTED PEER-REVIEWED PUBLICATIONS (20 of 56)

A full list of publications is available at:

<https://www.ncbi.nlm.nih.gov/myncbi/16Q4vwjVjxFke/bibliography/public/>

1. Johnatty SE, Pesaran T, Dolinsky J, Yussuf A et al. Case-case analysis addressing ascertainment bias for multigene panel testing implicates BRCA1 and PALB2 in endometrial cancer. *Hum Mutat.* 2021 Oct;42(10):1265-1278.
2. Quinn MCJ, McCue K, Shi W, Johnatty SE et al. Identification of a locus near *ULK1* associated with progression-free survival in ovarian cancer. *Cancer Epidemiol Biomarkers Prev.* 2021 Sep;30(9):1669-1680.
3. Nguyen A, O'Dwyer J, Vu T, ..., Johnatty SE et al. Generating high-quality data abstractions from scanned clinical records: text-mining-assisted extraction of endometrial carcinoma pathology features as proof of principle. *BMJ Open.* 2020 Jun 11;10(6):e037740.
4. Johnatty SE, Stewart CJR, Smith D, et al. Co-existence of leiomyomas, adenomyosis and endometriosis in women with endometrial cancer. *Sci Rep.* 2020 Feb 27;10(1):3621.
5. Johnatty SE, Stewart CJR, Smith D, Buchanan D et al. Risk and prognostic factors for endometrial carcinoma after diagnosis of breast or Lynch-associated cancers-a population-based analysis. *Cancer Med* 2018 Dec;7(12):6411-6422.
6. Johnatty SE, Tan YY, Buchanan DD, et al. Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. *Gynecol Oncol.* 2017 Nov;147(2):381-387.
7. Gao B, Lu Y, Nieuweboer AJM, Xu H, Beesley J, ... Johnatty SE, et al. Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. *Sci Rep.* 2018 Jan 24;8(1):1508.
8. Jordan SJ, Na R, Johnatty SE et al. Breastfeeding and Endometrial Cancer Risk: An analysis from the Epidemiology of Endometrial Cancer Consortium. *Obstet Gynecol* 2017 Jun;129(6):1059-1067.
9. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, ... Johnatty SE et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet.* 2017 May;49(5):680-691.
10. Ovarian Tumor Tissue Analysis (OTTA) Consortium...Johnatty SE et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncol.* 2017 Dec 1;3(12):e173290.
11. Johnatty SE et al. Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. *Clin Cancer Res.* 2015 Dec 1;21(23):5264-76.

12. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A... [Johnatty SE](#) et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol*. 2016 May;141(2):386-401.
13. Köbel M..., [Johnatty SE](#) et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. *Br J Cancer* 2014 Dec 9;111(12):2297-307.
14. Hedditch EL... [Johnatty SE](#) et al. ABCA Transporter Gene Expression is Associated with Poor Outcome in Epithelial Ovarian Cancer. *J Natl Cancer Inst*. 2014 Jun 23;106(7).
15. [Johnatty SE](#) et al. *ABCB1* (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. *Gynecol Oncol*. 2013 Oct;131(1):8-14.
16. Sieh W... [Johnatty SE](#) et al. Associations between hormone receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncol*. 2013 Aug;14(9):853-62.
17. Bojesen SE, Pooley KA, [Johnatty SE](#) et al. Multiple independent TERT variants associated with telomere length and risks of breast and ovarian cancer. *Nat Genet*. 2013 Apr;45(4):371-84.
18. Bolton KL... [Johnatty SE](#) et al. Association Between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer *JAMA*. 2012 Jan 25;307(4):382-90.
19. Bolton KL....[Johnatty SE](#) et al. A genome-wide association study of survival in ovarian cancer identifies a locus at chromosome 9 that is associated with susceptibility to ovarian cancer. *Nat Genet*. 2010 Oct;42(10):880-4.
20. [Johnatty SE](#) et al. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and *TERT*, a cancer susceptibility “hot-spot”. *PLoS Genetics* 2010 Jul 8;6(7).